{
    "clinical_study": {
        "@rank": "131047", 
        "arm_group": [
            {
                "arm_group_label": "PF-05175157, Midazolam", 
                "arm_group_type": "Experimental", 
                "description": "Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157"
            }, 
            {
                "arm_group_label": "Placebo, Midazolam", 
                "arm_group_type": "Experimental", 
                "description": "Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to assess the safety, tolerability and pharmacokinetics of multiple\n      oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight\n      and obese subjects."
        }, 
        "brief_title": "Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Overweight"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must meet all of the following inclusion criteria to be eligible for enrollment\n        into the study:\n\n          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive\n             (Healthy is defined as no clinically relevant abnormalities identified by a detailed\n             medical history, full physical examination, including blood pressure and pulse rate\n             measurement, 12 lead ECG and clinical laboratory tests).\n\n          -  Women must be of non childbearing potential.\n\n          -  Body Mass Index (BMI) of 25 to 35 kg/m2 inclusive; and a total body weight >50 kg\n             (110 lbs).\n\n          -  An informed consent document signed and dated by the subject.\n\n          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,\n             laboratory tests, and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at time of dosing).\n\n          -  Evidence or history of any chronic ongoing or current pulmonary disease.\n\n          -  History of smoking in the past 5 years and a history of smoking more than 10 pack\n             years, or history or evidence of habitual use of other (non smoked) tobacco or\n             nicotine containing products. Active ocular disease including infection, glaucoma,\n             seasonal allergies, dry eye symptoms or retinal/optic nerve disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807377", 
            "org_study_id": "B1731021"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-05175157, Midazolam", 
                "description": "200 mg tablet administered twice per day for 14 days", 
                "intervention_name": "PF-05175157", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-05175157, Midazolam", 
                "description": "2mg administered as single doses on Days 0 and 11", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo, Midazolam", 
                "description": "Placebo administered twice per day for 14 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Placebo, Midazolam", 
                "description": "2mg administered as single doses on Days 0 and 11", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 16, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731021&StudyName=Multiple%20Dose%20Safety%20Tolerability%2C%20Pharmacokinetics%20And%20Midazolam%20Interaction%20In%20Healthy%20Overweight%20And%20Obese%20Subjects%0A"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Chula Vista", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91911"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Placebo-Controlled Study To Assess Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 Administered In A Tablet Formulation In Otherwise Healthy Overweight And Obese Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Single Dose", 
                "measure": "Maximum Observed Plasma PF-05175157 Concentration  (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0 - 10 hrs postdose"
            }, 
            {
                "description": "Single Dose", 
                "measure": "Area Under the Curve from Time Zero to end of dosing interval for PF-05175157 (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "0 - 10 hrs postdose"
            }, 
            {
                "description": "Single Dose", 
                "measure": "Time to Reach Maximum Observed Plasma PF-05175157 Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0 - 10 hrs postdose"
            }, 
            {
                "description": "Steady State", 
                "measure": "Maximum Observed Plasma PF-05175157 Concentration  (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "description": "Steady State", 
                "measure": "Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-05175157", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "description": "Steady State", 
                "measure": "Time to Reach Maximum Observed Plasma PF-05175157 Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "measure": "Apparent Oral Clearance of PF-05175157 (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "measure": "Accumulation Ratio of PF-05175157 (Rac)", 
                "safety_issue": "No", 
                "time_frame": "0 - 10 hours postdose"
            }, 
            {
                "measure": "Plasma Decay Half-Life of PF-05175157 (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "measure": "Apparent Volume of Distribution of PF-05175157 (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "description": "Amount of PF-05175157 recovered in urine over 24 hours", 
                "measure": "Urinary Recovery for PF-05175157 (AE24)", 
                "safety_issue": "No", 
                "time_frame": "0 - 24 hours postdose"
            }, 
            {
                "measure": "Renal Clearance for PF-05175157 (CLr)", 
                "safety_issue": "No", 
                "time_frame": "0 - 24 hours post dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration for midazolam [AUC (0-t)]", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time for midazolam [AUC (0 - inf)]", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration for midazolam (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma midazolam Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours post dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life of midazolam (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0 - 48 hours postdose"
            }, 
            {
                "measure": "Fasting triglycerides", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Total cholesterol", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "LDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "HDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807377"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}